Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astri Therapeutics Inc (NQ: ATXS )

11.14 -0.32 (-2.79%)
Streaming Delayed Price Updated: 12:24 PM EDT, Oct 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astri Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Investment Conferences
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients... 
Via Benzinga
Astria Therapeutics Commences Initial-Stage Skin Disorder Study, Sees Preliminary Data By Year-end
Astria Therapeutics (NASDAQ: ATXS) announced initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects. STAR-0215 is designed to provide long-acting, effective attack prevention for... 
Via Benzinga
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Astria Therapeutics Gets FDA Nod For Initial-Stage Hereditary Angioedema Study
The U.S. Food and Drug Administration (FDA) announced clearance to Astria Therapeutics’ (NASDAQ: ATXS) Investigational New Drug (IND) application for STAR-0215 in the treatment of Hereditary Angioedema... 
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Names Chris Morabito Chief Medical Officer
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference
From Astria Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million. 
Via Benzinga
Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
From Astria Therapeutics
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
62 Biggest Movers From Yesterday
Gainers Missfresh Limited (NASDAQ: MF) jumped 51.1% to close at $0.2450 on Wednesday. 
Via Benzinga
Astria Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.